A team of researchers from IIIT-A has zeroed in on some common medicines that may hold promise as multi-target drugs treatment for both Small cell lung cancer (SCLC) and Covid-19 patients. The team has been working on developing a treatment for SCLC patients who are infected with Covid-19. During the Covid-19 pandemic, treatment of the SCLC patients became very challenging as they were more vulnerable to Covid-19. To avoid this situation, in-house treatments were recommended for them. From the in silico analysis, some drug molecules like Dacomitinib and Paclitaxel were identified as potent drug candidates against SCLC patients affected by Covid-19. It is conceivable that this treatment may reduce the drug load on the patients. However, the effectiveness of the identified drugs needs to be further validated in wet laboratories. Dr Sintu Kumar Samanta, Assistant professor from Dept. of Applied Sciences at IIIT-A is the principal investigator of this research project.